These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23993690)

  • 1. [Exception drugs status: specific characteristics and the role in the proper use of drugs].
    Gridchyna I; Baumevieille M; Aulois-Griot M; Bégaud B
    Rev Epidemiol Sante Publique; 2013 Oct; 61(5):485-92. PubMed ID: 23993690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement.
    Verger P; Rolland S; Paraponaris A; Bouvenot J; Ventelou B
    Fundam Clin Pharmacol; 2010 Aug; 24(4):509-16. PubMed ID: 19840120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cohort study of therapeutic prescriptions after the end of phytotherapy drug reimbursement by French Social Security.
    Riou França L; Vidal C; Bourechak N; Jeunne PL; Deville GS; Massol J
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):760-8. PubMed ID: 23208799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement].
    Wilkowsky C; Lenain A; Benbekhaled K; Le Gall MJ; Vignot S
    Bull Cancer; 2016 Apr; 103(4):353-60. PubMed ID: 27017057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid program; Drug Use Review program and electronic claims management system for outpatient drug claims--HCFA. Interim final rule with comment period.
    Fed Regist; 1992 Nov; 57(212):49397-412. PubMed ID: 10122482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.
    LaVange LM; Silverman HA
    Natl Med Care Util Expend Surv B; 1987 Apr; (12):1-43. PubMed ID: 10313516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Generic drugs in the medical-economic context of drug prescriptions].
    Bouvenot G; Villani P; Bouvenot J
    Presse Med; 2002 Jul; 31(24):1109-14. PubMed ID: 12162093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
    Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
    J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
    Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
    Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reimbursement of opiate substitution drugs to militaries in 2007].
    d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V
    Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physician versus 'off-label" ordinance].
    Kordus K; Spiewak R
    Przegl Lek; 2015; 72(1):38-41. PubMed ID: 26076577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Potentially inappropriate prescriptions for the elderly: a study of health insurance reimbursements in Southeastern France].
    Jardin M; Bocquier A; Cortaredona S; Nauleau S; Millon C; Savard-Chambard S; Allaria-Lapierre V; Sciortino V; Bouvenot G; Verger P
    Rev Epidemiol Sante Publique; 2012 Apr; 60(2):121-30. PubMed ID: 22418446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain.
    Zara C; Torralba M; Sotoca JM; Prat A; Faixedas MT; Gilabert A
    Ann Pharmacother; 2005 Jan; 39(1):177-82. PubMed ID: 15572601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug utilization review on a surgical intensive care unit.
    Marschner JP; Thürmann P; Harder S; Rietbrock N
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):447-51. PubMed ID: 7820326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.